Previous 10 | Next 10 |
Marinus Pharmaceuticals (NASDAQ:MRNS) said it received $30M in funding under an existing Oaktree Capital Management credit agreement. The company said the additional funding became available as a result of the U.S. Food and Drug Administration’s recent approval of the company’s&...
BARDA research contract extended through 2023 Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has received $30 million in funding under the exis...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
Truist analyst Joon Lee raised the price target on Marinus Pharmaceuticals (NASDAQ:MRNS +4.9%) to $50 from $35 and maintains a Buy rating on the shares. The analyst cites the company's Q4 results and additional updates on the planned launch of Ztalmy, stating that its annualized pricing of $1...
Marinus Pharmaceuticals, Inc. (MRNS) Q4 2021 Results Conference Call March 21, 2022 08:00 AM ET Company Participants Sasha Damouni - VP, IR and Corporate Communications Dr. Scott Braunstein - Chief Executive Officer Dr. Joe Hulihan - Chief Medical Officer Kimberly McCormick - Senior Vice Pres...
After a sharp rise following the U.S. approval of its seizure therapy Ztalmy last week, Radnor, Pennsylvania-based Marinus Pharmaceuticals (MRNS -11.7%) has recorded its biggest intra-day loss in nearly a month on Monday in reaction to its worse-than-expected Q4 2021 financials. After a ~1% Y...
Marinus Pharmaceuticals press release (NASDAQ:MRNS): Q4 GAAP EPS of -$0.77 misses by $0.02. Revenue of $1.52M (-1.3% Y/Y) misses by $1.98M. Shares -7.7% PM. “This year has already proven to be pivotal for Marinus following the FDA’s approval of ZTALMY®, the first and only t...
Received FDA approval of ZTALMY ® (ganaxolone) for the treatment of seizures associated with CDKL5 deficiency disorder; first approved treatment for this rare form of genetic epilepsy Awarded a Rare Pediatric Disease Priority Review Voucher by the FDA Eligible for an ...
Radnor, Pennsylvania-based Marinus Pharmaceuticals (NASDAQ:MRNS +26.8%) is trading sharply higher on Friday after the company announced the U.S. Food and Drug Administration (FDA) approved seizure treatment Ztalmy. The FDA has cleared Ztalmy, known as ganaxolone in generic terms, for the trea...
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older 1 ZTALMY significantly reduced major motor seizure frequency in CDD patients in the pivotal Marigold trial Rare Pediatric Disea...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...